Serum superoxide dismutase, a potential predictor for radiation pneumonitis following chemoradiotherapy in non-small cell lung cancer patients.

Abstract

PURPOSE:

To explore serum superoxide dismutase (SOD) for predicting radiation pneumonitis (RP) in non-small cell lung cancer patients following chemoradiotherapy.

METHODS:

Serum levels for SOD were measured by enzyme-linked immunosorbent assays prior to radiation therapy (Pre-RT) and post 40 Gy/4 weeks during the treatment (Pos-RT).

RESULTS:

SOD concentrations after delivery of 40 Gy/4 weeks was associated with the development of RP. The best predictive ability of SOD was observed for a cut-off value of 56 unit/ml, with a sensitivity of 0.80 (95% CI 0.28-0.99), and a specificity of 0.67 (95% CI 0.43-0.65) (p = 0.040).

CONCLUSION:

Serum SOD may be a potential predictor for RP, which need to be further verified.

• Authors: Dongqing Wang, Jingyu Zhu, Mingping Sun, Baosheng Li, Ling Wei, Zhongtang Wang, Hongfu Sun
• Journal: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (Biomarkers) Vol. 17 Issue 5 Pg. 455-62 (Aug 2012) ISSN: 1366-5804 [Electronic] England
• PMID: 22590985 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antigens, Neoplasm
• Chemokine CCL3
• Interleukin-6
• Keratin-19
• Transforming Growth Factor beta1
• antigen CYFRA21.1
• Intercellular Adhesion Molecule-1
• Superoxide Dismutase

Topics

• Antigens, Neoplasm (blood)
• Carcinoma, Non-Small-Cell Lung (therapy)
• Chemokine CCL3 (blood)
• Chemoradiotherapy (adverse effects)
• Enzyme-Linked Immunosorbent Assay (methods)
• Female
• Humans
• Intercellular Adhesion Molecule-1 (blood)
• Interleukin-6 (blood)
• Keratin-19 (blood)
• Lung Neoplasms (therapy)
• Male
• Middle Aged
• Predictive Value of Tests
• Prognosis
• Radiation Pneumonitis (blood, diagnosis, etiology)
• Reproducibility of Results
• Sensitivity and Specificity
• Superoxide Dismutase (blood)
• Time Factors
• Transforming Growth Factor beta1 (analysis)
• Treatment Outcome